New drug combo may keep liver cancer at bay after transplant

NCT ID NCT02081755

First seen Jan 29, 2026 · Last updated May 24, 2026 · Updated 21 times

Summary

This study looks at whether a drug called everolimus can help prevent liver cancer from coming back after a liver transplant. About 336 adults with high-risk liver cancer will receive either everolimus plus tacrolimus or standard drugs. The main goal is to see how long patients live without their cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Baylor University Medical Center

    Dallas, Texas, 75246, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Mount Sinai Medical Center

    New York, New York, 10029, United States

  • Northwestern University School of Medicine

    Chicago, Illinois, 60611, United States

  • University of California at San Francisco

    San Francisco, California, 94143, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Tennessee- Methodist University Hospital

    Memphis, Tennessee, 38104, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.